JP2010502979A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502979A5
JP2010502979A5 JP2009527200A JP2009527200A JP2010502979A5 JP 2010502979 A5 JP2010502979 A5 JP 2010502979A5 JP 2009527200 A JP2009527200 A JP 2009527200A JP 2009527200 A JP2009527200 A JP 2009527200A JP 2010502979 A5 JP2010502979 A5 JP 2010502979A5
Authority
JP
Japan
Prior art keywords
individual
liver
liver disease
adma
suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009527200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502979A (ja
JP4949473B2 (ja
Filing date
Publication date
Priority claimed from GBGB0617581.4A external-priority patent/GB0617581D0/en
Application filed filed Critical
Publication of JP2010502979A publication Critical patent/JP2010502979A/ja
Publication of JP2010502979A5 publication Critical patent/JP2010502979A5/ja
Application granted granted Critical
Publication of JP4949473B2 publication Critical patent/JP4949473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009527200A 2006-09-07 2007-09-07 肝機能を評価するためのバイオマーカー Active JP4949473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0617581.4A GB0617581D0 (en) 2006-09-07 2006-09-07 Biomarkers for assessing liver function
GB0617581.4 2006-09-07
PCT/GB2007/003362 WO2008029145A1 (en) 2006-09-07 2007-09-07 Biqmarkers for assessing liver function

Publications (3)

Publication Number Publication Date
JP2010502979A JP2010502979A (ja) 2010-01-28
JP2010502979A5 true JP2010502979A5 (https=) 2010-10-21
JP4949473B2 JP4949473B2 (ja) 2012-06-06

Family

ID=37232490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527200A Active JP4949473B2 (ja) 2006-09-07 2007-09-07 肝機能を評価するためのバイオマーカー

Country Status (16)

Country Link
US (1) US8455220B2 (https=)
EP (1) EP2059817B1 (https=)
JP (1) JP4949473B2 (https=)
KR (1) KR20090083335A (https=)
AT (1) ATE488772T1 (https=)
AU (1) AU2007293302A1 (https=)
CA (1) CA2662597A1 (https=)
DE (1) DE602007010644D1 (https=)
EA (1) EA200970256A1 (https=)
ES (1) ES2353835T3 (https=)
GB (1) GB0617581D0 (https=)
IL (1) IL197271A0 (https=)
MX (1) MX2009002378A (https=)
NO (1) NO20090993L (https=)
WO (1) WO2008029145A1 (https=)
ZA (1) ZA200901432B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2823349T3 (es) 2011-05-31 2021-05-06 Univ Colorado Regents Procedimiento para evaluación de la función hepática y el flujo sanguíneo portal
CA2891281C (en) 2012-11-12 2023-11-28 The Regents Of The University Of Colorado, A Body Corporate Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
WO2014190170A1 (en) * 2013-05-22 2014-11-27 The Regents Of The University Of California Biomarker composite test for hepatic vein pressure gradient and cirrhosis treatment
US10335452B2 (en) * 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
CN105181692A (zh) * 2015-09-30 2015-12-23 山东博科生物产业有限公司 一种缺血修饰白蛋白比色法检测试剂盒
ES2761266T3 (es) * 2015-11-10 2020-05-19 Inst Nat Sante Rech Med Métodos para predicción del tiempo de supervivencia de los pacientes con cirrosis alcohólica descompensada
US20220018852A1 (en) * 2018-11-20 2022-01-20 Inserm (Institute National De Ka Santé Et De La Recherche Médicale) Methods and kits for detecting liver dysfunction in a subject
CN121331222B (zh) * 2025-12-15 2026-03-10 北京大学 基于蛋白质组的慢性肝脏疾病发病预测的蛋白组合、预测模型及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
CA2415174A1 (en) * 2000-07-06 2002-01-17 Thomas W. Bell Methods and kits for the detection of arginine compounds
WO2003046538A1 (en) * 2001-11-26 2003-06-05 Ischemia Technologies, Inc. Electrochemical detection of ischemia
AU2003261424A1 (en) * 2002-08-06 2004-02-23 Nitromed, Inc. Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
AU2003290784A1 (en) 2002-11-15 2004-06-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for detecting asymmetric dimethylarginine in a biological sample
WO2005039598A1 (en) 2003-10-24 2005-05-06 Intermune, Inc. Method of treating alcoholic liver disease
DE10351238A1 (de) * 2003-11-03 2005-06-02 Roche Diagnostics Gmbh Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern

Similar Documents

Publication Publication Date Title
JP2010502979A5 (https=)
Duseja et al. APACHE II score is superior to SOFA, CTP and MELD in predicting the short‐term mortality in patients with acute‐on‐chronic liver failure (ACLF)
Bruchim et al. Pathophysiology of heatstroke in dogs–revisited
Sarin et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014
Bureau et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease
Lee et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study
Kahli et al. Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass
RU2009139295A (ru) Биомаркеры и биомаркерные признаки почечной сохранности, обладающие предсказательной силой, для использования в мониторинге состояния почек
BR112012006678A2 (pt) método para criar um arranjo proteico, arranjo proteico e métodos para determinar a especificidade da ligação de um anticorpo ou preparação de anticorpos, para determinar biomarcadores de doenças, para diagnosticar uma doença, para monitorar as vias de transdução de sinais e para determinar interações entre pequenas moléculas e proteínas
JP2011510327A5 (https=)
Aleem et al. Correlation of C-reactive protein levels with severity of chronic urticaria
Zhang et al. EPAS1 and VEGFA gene variants are related to the symptoms of acute mountain sickness in Chinese Han population: a cross-sectional study
Pelucchi et al. Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFE‐related hemochromatosis
Wang et al. CXCL5 is associated with the increased risk of coronary artery disease
Kiliś-Pstrusińska et al. The rs1800471 polymorphism of TGFB1 gene, serum TGF-beta1 level and chronic kidney disease progression
Guzmán-Bárcenas et al. Clara cell protein expression in mechanically ventilated term and preterm infants with respiratory distress syndrome and at risk of bronchopulmonary dysplasia: a pilot study
JP2018502559A5 (https=)
Paradis et al. Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease
Yatera et al. Severe dyslipidaemia, atherosclerosis, and sudden cardiac death in mice lacking all NO synthases fed a high-fat diet
Ou-Yang et al. Plasma clusterin concentrations may predict resistance to intravenous immunoglobulin in patients with Kawasaki disease
Genovesi et al. Baroreceptor sensitivity and baroreceptor effectiveness index in cirrhosis: the relevance of hepatic venous pressure gradient
Vukobrat-Bijedic et al. Use of Serum Levels of Proinflammatory Cytokine IL–1α in Chronic Hepatitis B
Kumar et al. Genetic variation in CCDC93 is associated with elevated central systolic blood pressure, impaired arterial relaxation, and mitochondrial dysfunction
Ostrovsky et al. On the issue of polymorbidity and comorbidity in patients with COPD
Meegan et al. Transpulmonary generation of cell‐free hemoglobin contributes to vascular dysfunction in pulmonary arterial hypertension via dysregulated clearance mechanisms